{"filing":{"accession_number":"0001193125-26-332802","cik":"0001515673","ticker":"RARE","company_name":"Ultragenyx Pharmaceutical Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"rare-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-20260804.htm"},"events":[{"id":23897,"run_id":21614,"accession_number":"0001193125-26-332802","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Ultragenyx's financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenue of $214 million, net loss of $92 million, and detailed product revenue breakdowns. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing also reaffirms full-year 2026 guidance and discusses upcoming clinical and regulatory catalysts.","company_name":"Ultragenyx Pharmaceutical Inc.","ticker":"RARE","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24254,"accession_number":"0001193125-26-332802","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Ultragenyx's financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenue of $214 million, net loss of $92 million, and detailed product revenue breakdowns. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing also reaffirms full-year 2026 guidance and discusses upcoming clinical and regulatory catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:26:02.682834+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24254,"accession_number":"0001193125-26-332802","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Ultragenyx's financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenue of $214 million, net loss of $92 million, and detailed product revenue breakdowns. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing also reaffirms full-year 2026 guidance and discusses upcoming clinical and regulatory catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:26:02.682834+00:00","company_name":"Ultragenyx Pharmaceutical Inc.","ticker":"RARE","filing_date":"2026-08-04"}]}